Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma

Neoplasia (United States)

Volumn 15, Issue 12, 2013, Pages 1400-1409

  Iannone, Raffaella ^a   Miele, Lucio ^b   Maiolino, Piera ^c   Pinto, Aldo ^a   Morello, Silvana ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ALLOPHYCOCYANIN; BAY 60 6583; CD11 ANTIGEN; CD11B ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; GAMMA INTERFERON; GEM; GEMCITABINE; GRANZYME B; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; OXALIPLATIN; PSB 1115; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 1 PROPYL 8 (4 SULFOPHENYL)XANTHINE; 1-PROPYL-8-(4-SULFOPHENYL)XANTHINE; ADENOSINE A2B RECEPTOR; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BAY 60-6583; CCL2 PROTEIN, MOUSE; IL10 PROTEIN, MOUSE; IMMUNOSUPPRESSIVE AGENT; XANTHINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE TUMOR; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CANCER TRANSPLANTATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL MELANOMA; IMMUNOLOGY; METABOLISM; NATURAL KILLER T CELL; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR VOLUME;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMOKINE CCL2; DACARBAZINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYELOID CELLS; NATURAL KILLER T-CELLS; NEOPLASM TRANSPLANTATION; RECEPTOR, ADENOSINE A2B; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; XANTHINES;

EID: 84891612009     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131748     Document Type: Article

References (45)

1. Stagg J and Smyth MJ (2010). Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29, 5346-5358.
2. Sorrentino R, Pinto A, and Morello S (2013). The adenosinergic system in cancer: key therapeutic target. Oncoimmunology 2, e22448.
3. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, et al. (2006). A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103, 13132-13137.
4. + T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia 13, 365-373.
5. + T cells reduces melanoma growth in mice. PLoS One 7, e45401.
6. Haskó G, Csóka B, Németh ZH, Vizi ES, and Pacher P (2009). A2B adenosine receptors in immunity and inflammation. Trends Immunol 30, 263-270.
7. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, and Feoktistov I (2008). Host A2B adenosine receptors promote carcinoma growth. Neoplasia 10, 987-995.
8. Zeng D, Maa T, Wang U, Feoktistov I, Biaggioni I, and Belardinelli L (2003). Expression and function of A2B adenosine receptors in the U87MG tumor cells. Drug Dev Res 58, 405-411.
9. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennon S, Baraldi PC, and Borea PA (2007). Caffeine inhibits adenosineinduced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72, 395-406.
10. + cells. J Immunol 187, 6120-6129.
11. + cells". J Immunol 188, 2929-2930.
12. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, and Linden J (2012). Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 188, 198-205.
13. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
14. Zikich D, Schachter J, and Besser MJ (2013). Immunotherapy for the management of advanced melanoma: the next steps. Am J Clin Dermatol 14, 261-272.
15. Callahan MK, Postow MA, and Wolchok JD (2013). Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 31, 191-199.
16. Blanchard T, Srivastava PK, and Duan F (2013). Vaccines against advanced melanoma. Clin Dermatol 31, 179-190.
17. Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, and Levesque MP (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy 5, 169-182.
18. Marigo I, Dolcetti L, Serafini P, Zanovello P, and Bronte V (2008). Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222, 162-179.
19. Ostrand-Rosenberg S and Sinha P (2009). Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182, 4499-4506.
20. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, and Mandruzzato S (2012). Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35, 107-115.
21. Gabrilovich DI, Ostrand-Rosenberg S, and Bronte V (2012). Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12, 253-268.
22. Serafini P, Borrello I, and Bronte V (2006). Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16, 53-65.
23. Gabrilovich DI and Nagaraj S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174.
24. Umansky V and Sevko A (2012). Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 22, 319-326.
25. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, Arra C, Cicala C, Pinto A, and Morello S (2012). Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol 189, 2226-2233.
26. Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, et al. (2007). Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115, 1581-1590.
27. Eckle T, Grenz A, Laucher S, and Eltzschig HK (2008). A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118, 3301-3315.
28. Hart ML, Jacobi B, Schittenhelm J, Henn M, and Eltzschig HK (2009). Cutting edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 182, 3965-3968.
29. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, and Smyth MJ (2010). Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 107, 1547-1552.
30. Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A, Filipek B, Zimmer A, and Müller CE (2004). Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther 308, 358-366.
31. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11, 6713-6721.
32. Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, and Conrad DH (2012). Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol 189, 511-515.
33. Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, and Mignot G (2013). Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol 133, 499-508.
34. Umansky V and Sevko A (2012). Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 61, 275-282.
35. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, and Montero AJ (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58, 49-59.
36. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, et al. (2011). Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108, 17111-17116.
37. Khan KH, Goody RB, Hameed H, Jalil A, Coyle VM, and McAleer JJ (2012). Metastatic melanoma: a regional review and future directions. Tumori 98, 575-580.
38. Junger WG (2011). Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 11, 201-212.
39. Zhang B (2010). CD73: a novel target for cancer immunotherapy. Cancer Res 70, 6407-6411.
40. Novitskiy S, Ryzhov S, Zaynagetdinov R, Goldstein A, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, et al. (2008). Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822-1831.
41. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J, Cheng P, Cho H, Celis E, Quiceno DG, Padhya T, et al. (2010). HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207, 2439-2453.
42. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, et al. (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205, 2235-2249.
43. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, and Srikrishna G (2008). Proinflammatory S100 proteins regulate the accumulation of myeloidderived suppressor cells. J Immunol 181, 4666-4675.
44. Hochwald C, Kennedy K, Chang J, and Moya F (2002). A randomized, controlled, double-blind trial comparing two loading doses of aminophylline. J Perinatol 22, 275-278.
45. Nuhoglu Y and Nuhoglu C (2008). Aminophylline for treating asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med 2, 305-313.